CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to...

Source: Journal of Hematology and Oncology - August 3, 2023 Category: Hematology Authors: Xinyuan Liu, Juanjuan Zhao, Xiangqian Guo and Yongping Song Tags: Correspondence Source Type: research